August 13, 2024 03:00 PM EDT
R&D

Rivus posts a win for its ex­per­i­men­tal obe­si­ty drug in heart fail­ure pa­tients

Max Bayer

Pharma Reporter

Rivus Phar­ma­ceu­ti­cals’ ex­per­i­men­tal car­diometa­bol­ic drug, HU6, nailed a mid-stage tri­al in obese pa­tients with heart fail­ure, find­ing that pa­tients notched a sta­tis­ti­cal­ly sig­nif­i­cant re­duc­tion in …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

Jazz wins ap­proval for bis­pe­cif­ic in bil­iary tract can­cer

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

At Jef­feries, all that man­u­fac­tur­ers want to talk about is GLP-1s

FDA ad­comm rais­es risk ques­tions on As­traZeneca’s An­dexxa

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times